接受奈玛特韦/利托那韦或莫努匹拉韦治疗新冠病毒的慢性淋巴细胞白血病患者中新冠病毒感染的反弹情况。 - Suppr | 超能文献

相似文献

1

Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.接受奈玛特韦/利托那韦或莫努匹拉韦治疗新冠病毒的慢性淋巴细胞白血病患者中新冠病毒感染的反弹情况。

Leuk Lymphoma. 2023 May;64(5):1054-1056. doi: 10.1080/10428194.2023.2183732. Epub 2023 Mar 13.

2

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择

Acta Med Indones. 2022 Oct;54(4):638-644.

3

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.在欧洲血液系统恶性肿瘤高危COVID-19患者中，莫努匹韦与奈玛特韦/利托那韦的比较。来自EPICOVIDEHA注册研究的配对分析。

Int J Antimicrob Agents. 2023 Oct;62(4):106952. doi: 10.1016/j.ijantimicag.2023.106952. Epub 2023 Aug 13.

4

Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.奈玛特韦/利托那韦与莫努匹韦治疗 COVID-19 的疗效和安全性比较：系统评价和荟萃分析。

J Med Virol. 2023 Jun;95(6):e28889. doi: 10.1002/jmv.28889.

5

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.口服抗病毒药物利托那韦-奈玛特韦和莫努匹韦在多发性骨髓瘤患者中的使用与 COVID-19 重症率低相关：一项单中心前瞻性研究。

Viruses. 2023 Mar 8;15(3):704. doi: 10.3390/v15030704.

6

Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后出现症状反弹的临床、病毒学和免疫学评估。

Clin Infect Dis. 2023 Feb 18;76(4):573-581. doi: 10.1093/cid/ciac663.

7

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.莫努匹韦和奈玛特韦-利托那韦：口服冠状病毒病 2019 抗病毒药物。

Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180.

8

Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后复发。

J Med Virol. 2023 Feb;95(2):e28430. doi: 10.1002/jmv.28430.

9

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.奈玛特韦/利托那韦或莫努匹韦治疗后 COVID-19 反弹的临床特征：一项前瞻性队列研究。

Medicine (Baltimore). 2023 Sep 29;102(39):e35094. doi: 10.1097/MD.0000000000035094.

10

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.尼马瑞韦/利托那韦与莫努匹韦联合治疗持续性 SARS-CoV-2 感染：病例报告和文献综述。

Int J Infect Dis. 2023 Aug;133:53-56. doi: 10.1016/j.ijid.2023.04.412. Epub 2023 May 5.

引用本文的文献

1

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".新冠病毒感染使用奈玛特韦-利托那韦（帕罗韦德）治疗后寻求医疗护理的风险因素：“症状反弹”

Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.

2

SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis.接受抗病毒药物、恢复期血浆或未接受治疗的患者中 SARS-CoV-2 感染复发：系统评价与荟萃分析。

Blood Transfus. 2024 Nov;22(6):537-550. doi: 10.2450/BloodTransfus.764. Epub 2024 May 27.

3

SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.